Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.

Published byGregory Cole Modified over 5 years ago

Similar presentations

Presentation on theme: "Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic."— Presentation transcript:

1 Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation  Raymond Wong, Munir Shahjahan, Xuemei Wang, Peter F. Thall, Marcos de Lima, Issa Khouri, James Gajewski, Jorge Alamo, Daniel Couriel, Borje S. Andersson, Michelle Donato, Chitra Hosing, Krishna Komanduri, Paolo Anderlini, Jeffrey Molldrem, Naoto T. Ueno, Elihu Estey, Cindy Ippoliti, Richard Champlin, Sergio Giralt  Biology of Blood and Marrow Transplantation  Volume 11, Issue 2, Pages (February 2005) DOI: /j.bbmt Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Kaplan-Meier curve for survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Kaplan-Meier curve for event-free survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Kaplan-Meier curve for nonrelapse mortality-free survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Effect of tacrolimus AUC on event-free survival. Row 1 includes patients with a peripheral blood blast count of 0 and is modeled with a tacrolimus AUC at the 10th, 50th, and 90th percentiles. Row 2 depicts outcomes for patients with an absolute peripheral blood blast count of 80/dL. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic."

Similar presentations

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J

Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.

CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.
Clofarabine ± Fludarabine with Once Daily i. v

Clofarabine ± Fludarabine with Once Daily i. v
Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.

Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Similar presentations

Ads by Google